SG11202010915XA - Rip1 inhibitory compounds and methods for making and using the same - Google Patents

Rip1 inhibitory compounds and methods for making and using the same

Info

Publication number
SG11202010915XA
SG11202010915XA SG11202010915XA SG11202010915XA SG11202010915XA SG 11202010915X A SG11202010915X A SG 11202010915XA SG 11202010915X A SG11202010915X A SG 11202010915XA SG 11202010915X A SG11202010915X A SG 11202010915XA SG 11202010915X A SG11202010915X A SG 11202010915XA
Authority
SG
Singapore
Prior art keywords
making
methods
same
inhibitory compounds
rip1
Prior art date
Application number
SG11202010915XA
Other languages
English (en)
Inventor
Esteban Masuda
Simon Shaw
Vanessa Taylor
Somasekhar Bhamidipati
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of SG11202010915XA publication Critical patent/SG11202010915XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02Seven-membered rings
    • C07D267/08Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11202010915XA 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same SG11202010915XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862666462P 2018-05-03 2018-05-03
PCT/US2019/030476 WO2019213447A1 (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Publications (1)

Publication Number Publication Date
SG11202010915XA true SG11202010915XA (en) 2020-12-30

Family

ID=66530556

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010915XA SG11202010915XA (en) 2018-05-03 2019-05-02 Rip1 inhibitory compounds and methods for making and using the same

Country Status (34)

Country Link
US (7) US10815206B2 (es)
EP (2) EP3788044B1 (es)
JP (4) JP2021523226A (es)
KR (1) KR20210005222A (es)
CN (1) CN112368278A (es)
AU (2) AU2019262144B2 (es)
BR (1) BR112020022420A2 (es)
CA (1) CA3099037A1 (es)
CL (1) CL2020002841A1 (es)
CO (1) CO2020015156A2 (es)
CR (1) CR20200581A (es)
DK (1) DK3788044T3 (es)
DO (2) DOP2020000198A (es)
EA (1) EA202092580A1 (es)
EC (1) ECSP20078326A (es)
ES (1) ES2956087T3 (es)
FI (1) FI3788044T3 (es)
HR (1) HRP20231381T1 (es)
HU (1) HUE063896T2 (es)
IL (2) IL278417B2 (es)
JO (1) JOP20200278A1 (es)
LT (1) LT3788044T (es)
MA (1) MA52488B1 (es)
MD (1) MD3788044T2 (es)
MX (1) MX2020011621A (es)
PE (1) PE20211383A1 (es)
PH (1) PH12020551847A1 (es)
PL (1) PL3788044T3 (es)
PT (1) PT3788044T (es)
RS (1) RS64736B1 (es)
SG (1) SG11202010915XA (es)
SI (1) SI3788044T1 (es)
WO (1) WO2019213447A1 (es)
ZA (2) ZA202007486B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
WO2019213447A1 (en) 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CN111138448B (zh) * 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) * 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
MX2022002717A (es) * 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
WO2021046515A1 (en) 2019-09-06 2021-03-11 Board Of Regents, The University Of Texas System Inhibitors of receptor interacting protein kinase i for the treatment of disease
MX2022002719A (es) * 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Inhibidores heterociclicos de la quinasa rip1.
AU2020353663A1 (en) 2019-09-27 2022-04-07 Board Of Regents, The University Of Texas System Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease
EP3861676A1 (en) * 2019-10-21 2021-08-11 Google LLC Verifiable consent for privacy protection
TW202132307A (zh) 2019-11-07 2021-09-01 美商雷傑製藥公司 雜環rip1抑制性化合物
CN114981248A (zh) * 2019-11-26 2022-08-30 德州大学***董事会 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
MX2022010693A (es) * 2020-02-28 2022-09-26 Univ Texas Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades.
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI824259B (zh) 2020-07-01 2023-12-01 美商雷傑製藥公司 Rip1k抑制劑
WO2022171111A1 (en) * 2021-02-10 2022-08-18 Zai Lab (Us) Llc Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof
CN114989156A (zh) * 2021-05-19 2022-09-02 成都贝诺科成生物科技有限公司 一种受体相互作用蛋白抑制剂及其制备方法和用途
AU2022328136A1 (en) 2021-08-10 2023-11-30 Abbvie Inc. Nicotinamide ripk1 inhibitors
WO2023114061A1 (en) 2021-12-16 2023-06-22 Rigel Pharmaceuticals, Inc. Crystalline forms of a ripk1 inhibitor
WO2023138317A1 (zh) * 2022-01-21 2023-07-27 中国科学院上海药物研究所 具有ripk1抑制活性的化合物、其制备方法及其用途
CN114736197B (zh) * 2022-06-13 2022-09-13 南京医工医药技术有限公司 咪唑啉酮衍生物及其用途
CN115353513A (zh) * 2022-07-29 2022-11-18 中国人民解放军海军军医大学 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
PT96059B (pt) 1989-12-04 1998-07-31 Searle & Co Sistema de camada unica para a administracao de um medicamento por via transdermica
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
JPH07502219A (ja) 1991-12-18 1995-03-09 ミネソタ マイニング アンド マニュファクチャリング カンパニー 多重層型バリアー構造体
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
US20090099242A1 (en) 2007-08-15 2009-04-16 Cuny Gregory D Heterocyclic inhibitors of necroptosis
TWI637951B (zh) * 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
WO2016027253A1 (en) * 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
WO2016128936A1 (en) 2015-02-13 2016-08-18 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
JP6785252B2 (ja) * 2015-07-02 2020-11-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二環式ラクタム及びその使用方法
DK3362449T3 (da) 2015-10-13 2021-07-19 Inst Nat Sante Rech Med Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
CA3002542C (en) 2015-10-23 2023-11-28 Takeda Pharmaceutical Company Limited Substituted azepin heterocyclic derivatives and compositions thereof useful as rip1 kinase inhibitor
WO2017109724A1 (en) 2015-12-21 2017-06-29 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CN109071504B (zh) * 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
JP2020509009A (ja) * 2017-02-27 2020-03-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としての複素環式アミド
WO2019213447A1 (en) * 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
MD3788045T2 (ro) * 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
US20210292340A1 (en) 2018-06-26 2021-09-23 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Cell necrosis inhibitor, preparation method therefor and use thereof
CN111138448B (zh) 2018-11-02 2022-08-02 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
WO2020088194A1 (zh) 2018-11-02 2020-05-07 中国科学院上海药物研究所 抑制rip1激酶的杂环酰胺及其用途
MX2022002719A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Inhibidores heterociclicos de la quinasa rip1.

Also Published As

Publication number Publication date
AU2019262144B2 (en) 2023-11-16
IL299784A (en) 2023-03-01
JP2022160665A (ja) 2022-10-19
EP4248975A3 (en) 2024-03-13
HUE063896T2 (hu) 2024-02-28
SI3788044T1 (sl) 2023-12-29
US20200407332A1 (en) 2020-12-31
EP3788044A1 (en) 2021-03-10
US20210009537A1 (en) 2021-01-14
JP2021523226A (ja) 2021-09-02
EP4248975A2 (en) 2023-09-27
US11472782B2 (en) 2022-10-18
RS64736B1 (sr) 2023-11-30
PL3788044T3 (pl) 2024-02-12
BR112020022420A2 (pt) 2021-03-02
JP7187729B2 (ja) 2022-12-12
ZA202007486B (en) 2022-06-29
PE20211383A1 (es) 2021-07-27
MX2020011621A (es) 2021-02-22
US20210040053A1 (en) 2021-02-11
JP2023022225A (ja) 2023-02-14
US20210238153A2 (en) 2021-08-05
MA52488B1 (fr) 2023-11-30
IL299784B2 (en) 2024-04-01
PT3788044T (pt) 2023-08-31
US10815206B2 (en) 2020-10-27
IL278417B2 (en) 2024-05-01
MD3788044T2 (ro) 2023-12-31
PH12020551847A1 (en) 2021-06-28
ECSP20078326A (es) 2021-03-31
US11377428B2 (en) 2022-07-05
ZA202108603B (en) 2022-03-30
DOP2023000169A (es) 2023-10-15
EA202092580A1 (ru) 2021-04-07
US11332451B2 (en) 2022-05-17
JP7367169B2 (ja) 2023-10-23
LT3788044T (lt) 2023-11-10
IL278417A (es) 2020-12-31
US20210002236A1 (en) 2021-01-07
AU2019262144A1 (en) 2020-11-26
CL2020002841A1 (es) 2021-05-24
DOP2020000198A (es) 2021-04-30
US20190337907A1 (en) 2019-11-07
EP3788044B1 (en) 2023-08-09
IL278417B1 (en) 2024-01-01
US11370765B2 (en) 2022-06-28
CO2020015156A2 (es) 2021-02-26
US20210002237A1 (en) 2021-01-07
FI3788044T3 (fi) 2023-09-25
WO2019213447A1 (en) 2019-11-07
US20230113841A1 (en) 2023-04-13
CA3099037A1 (en) 2019-11-07
CN112368278A (zh) 2021-02-12
JP2024009916A (ja) 2024-01-23
AU2023254980A1 (en) 2023-11-16
KR20210005222A (ko) 2021-01-13
US11370764B2 (en) 2022-06-28
IL299784B1 (en) 2023-12-01
JOP20200278A1 (ar) 2020-11-03
MA52488A (fr) 2021-03-10
ES2956087T3 (es) 2023-12-13
CR20200581A (es) 2021-05-11
DK3788044T3 (da) 2023-10-02
HRP20231381T1 (hr) 2024-03-01

Similar Documents

Publication Publication Date Title
ZA202108603B (en) Rip1 inhibitory compounds and methods for making and using the same
IL291033A (en) rip1 inhibitory compounds and methods for their preparation and use
ZA202007487B (en) Rip1 inhibitory compounds and methods for making and using the same
IL290781A (en) rip1 inhibitory compounds and methods for their preparation and use
EP3746124A4 (en) COMPOUNDS AND USES THEREOF
PL3594199T3 (pl) Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
EP3899293A4 (en) LOCK NUT
IL277502A (en) Compounds and uses for them
SG11202009175RA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
SG11202009138QA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
IL283309A (en) rip1 inhibitors
IL279483A (en) Cyanotriazole compounds and their uses
EP3724933A4 (en) SUPRAL CONDUCTING COMPOUNDS AND METHOD FOR PRODUCING THEREOF
EP3743635A4 (en) ANTI-KICKBACK LOCK
GB201917427D0 (en) The flylead
GB201916822D0 (en) The degravitator
ZA201906782B (en) Mulcher
GB201904750D0 (en) The dehydrometer
GB201902293D0 (en) The hangit
GB201808686D0 (en) The dogtooth
AU2018902788A0 (en) 2018-05-25 6d
AU2018903548A0 (en) Substituted-pyridinyl compounds and uses thereof
GB201800634D0 (en) The Tasteaire